La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genetec Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Genetec ha un patrimonio netto totale di ¥2.1B e un debito totale di ¥925.0M, che porta il suo rapporto debito/patrimonio netto a 44%. Le sue attività totali e le sue passività totali sono rispettivamente ¥4.4B e ¥2.3B. L'EBIT di Genetec è ¥805.0M rendendo il suo rapporto di copertura degli interessi 100.6. Ha liquidità e investimenti a breve termine pari a ¥1.2B.

Informazioni chiave

44.0%

Rapporto debito/patrimonio netto

JP¥925.00m

Debito

Indice di copertura degli interessi	100.6x
Contanti	JP¥1.24b
Patrimonio netto	JP¥2.10b
Totale passività	JP¥2.28b
Totale attività	JP¥4.38b

Aggiornamenti recenti sulla salute finanziaria

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Aug 02

Recent updates

Positive Sentiment Still Eludes Genetec Corporation (TSE:4492) Following 34% Share Price Slump

Aug 05

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Aug 02

Genetec Corporation's (TSE:4492) Popularity With Investors Under Threat As Stock Sinks 27%

May 23

Genetec Corporation (TSE:4492) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected

Feb 26

Capital Allocation Trends At Genetec (TYO:4492) Aren't Ideal

Mar 28

Genetec Corporation (TYO:4492) Has A ROE Of 13%

Nov 23

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥3.0B ) di 4492 superano le sue passività a breve termine ( ¥1.7B ).

Passività a lungo termine: Le attività a breve termine di 4492 ( ¥3.0B ) superano le sue passività a lungo termine ( ¥540.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4492 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4492 è aumentato da 20% a 44% negli ultimi 5 anni.

Copertura del debito: Il debito di 4492 è ben coperto dal flusso di cassa operativo ( 65.1% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 4492 sono ben coperti dall'EBIT ( 100.6 x copertura).

Genetec Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Recent updates

First quarter 2025 earnings released: EPS: JP¥4.56 (vs JP¥1.67 loss in 1Q 2024)

Positive Sentiment Still Eludes Genetec Corporation (TSE:4492) Following 34% Share Price Slump

New major risk - Share price stability

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 15%

Genetec Corporation to Report Q1, 2025 Results on Aug 09, 2024

Genetec Corporation's (TSE:4492) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Genetec Corporation, Annual General Meeting, Jun 25, 2024

Investor sentiment deteriorates as stock falls 21%

Genetec Corporation to Report Fiscal Year 2024 Results on May 15, 2024

Upcoming dividend of JP¥6.50 per share

Genetec Corporation (TSE:4492) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected

Third quarter 2024 earnings released

Investor sentiment improves as stock rises 18%

New major risk - Share price stability

Investor sentiment improves as stock rises 20%

New major risk - Share price stability

Genetec Corporation to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released

Investor sentiment improves as stock rises 25%

Genetec Corporation to Report Q2, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: JP¥5.02 loss per share (vs JP¥34.94 loss in 1Q 2023)

Genetec Corporation to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥10.00 per share at 2.0% yield

Third quarter 2023 earnings released: JP¥13.22 loss per share (vs JP¥1.87 loss in 3Q 2022)

Genetec Corporation (TSE:4492) agreed to acquire Topwell Co., Ltd. from Yasuhide Inoue for ¥547 million.

Genetec Corporation to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released

Less than half of directors are independent

Genetec Corporation to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: JP¥34.94 loss per share (vs JP¥19.20 profit in 1Q 2022)

Genetec Corporation to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Genetec Corporation, Annual General Meeting, Jun 28, 2022

No independent directors

Genetec Corporation to Report Fiscal Year 2022 Results on May 16, 2022

Upcoming dividend of JP¥10.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Genetec Corporation (JASDAQ:4492) agreed to acquire BART Co., Ltd. from Hitoshi Fujita and others.

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS JP¥4.02 (vs JP¥8.13 in 2Q 2021)

Upcoming dividend of JP¥4.00 per share

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS JP¥94.39 (vs JP¥141 in FY 2020)

Capital Allocation Trends At Genetec (TYO:4492) Aren't Ideal

Upcoming dividend of JP¥8.00 per share

New 90-day low: JP¥1,846

New 90-day low: JP¥1,926

Genetec Corporation (TYO:4492) Has A ROE Of 13%

New 90-day high: JP¥2,421

New 90-day low - JP¥1,542

Genetec Corporation to Report Q1, 2021 Results on Aug 05, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane